人尾加压素 II 的心血管作用——高血压相关考量 - Suppr

Suppr

超能文献

Cardiovascular actions of human urotensin II--considerations for hypertension.

作者信息

Russell Fraser D, Molenaar Peter

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):271-3. doi: 10.1007/s00210-004-0876-y. Epub 2004 Feb 19.

DOI:10.1007/s00210-004-0876-y

PMID:14985940

Abstract

摘要

相似文献

Cardiovascular actions of human urotensin II--considerations for hypertension.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):271-3. doi: 10.1007/s00210-004-0876-y. Epub 2004 Feb 19.

Urotensin II: a vascular mediator in health and disease.

Curr Vasc Pharmacol. 2005 Apr;3(2):159-68. doi: 10.2174/1570161053586930.

[Urotensin II--a newly discovered modulator of cardiovascular functions in vertebrates].

Cesk Fysiol. 2013;62(1):19-25.

Serum urotensin II levels in patients with non-dipper hypertension.

Clin Exp Hypertens. 2013;35(7):506-11. doi: 10.3109/10641963.2012.758276. Epub 2013 Jan 9.

Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

Expert Opin Ther Targets. 2008 Mar;12(3):327-39. doi: 10.1517/14728222.12.3.327.

Role of urotensin II in atherosclerotic cardiovascular diseases.

Cardiovasc Revasc Med. 2008 Jul-Sep;9(3):166-78. doi: 10.1016/j.carrev.2008.02.001.

[Possible involvement of urotensin II in essential hypertension].

Nihon Rinsho. 2004 Sep;62 Suppl 9:727-9.

Human urotensin II as a link between hypertension and coronary artery disease.

Hypertens Res. 2006 Jun;29(6):375-87. doi: 10.1291/hypres.29.375.

Urotensin-II as an angiogenic factor.

Peptides. 2010 Jun;31(6):1219-24. doi: 10.1016/j.peptides.2010.03.022. Epub 2010 Mar 24.

Urotensin II: from osmoregulation in fish to cardiovascular regulation in man.

Br J Anaesth. 2007 May;98(5):557-9. doi: 10.1093/bja/aem088.

引用本文的文献

Desensitisation of native and recombinant human urotensin-II receptors.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Nov;380(5):451-7. doi: 10.1007/s00210-009-0441-9. Epub 2009 Aug 13.

Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.

Peptides. 2007 Aug;28(8):1483-9. doi: 10.1016/j.peptides.2007.04.018. Epub 2007 May 6.

Therapeutic potential of blockade of the urotensin II system in systemic hypertension.

Curr Hypertens Rep. 2007 Mar;9(1):53-8. doi: 10.1007/s11906-007-0010-x.

Enhancement of vascular smooth muscle cell migration by urotensin II.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Aug;373(5):381-6. doi: 10.1007/s00210-006-0086-x. Epub 2006 Aug 1.

Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Naunyn Schmiedebergs Arch Pharmacol. 2006 May;373(2):148-57. doi: 10.1007/s00210-006-0057-2. Epub 2006 Apr 5.

Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):347-52. doi: 10.1007/s00210-004-0991-9. Epub 2004 Oct 23.

本文引用的文献

Urotensin-II: a novel systemic hypertensive factor in the cat.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):274-80. doi: 10.1007/s00210-004-0873-1. Epub 2004 Feb 19.

Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.

Br J Pharmacol. 2003 Dec;140(7):1155-8. doi: 10.1038/sj.bjp.0705555.

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81. doi: 10.1152/ajpheart.00217.2003. Epub 2003 Jun 5.

Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney.

Am J Physiol Renal Physiol. 2003 Oct;285(4):F792-8. doi: 10.1152/ajprenal.00342.2002. Epub 2003 Jun 3.

Plasma urotensin in human systolic heart failure.

Circulation. 2002 Dec 3;106(23):2877-80. doi: 10.1161/01.cir.0000044388.19119.02.

Plasma urotensin II in heart failure.

Lancet. 2002 Aug 17;360(9332):545-6. doi: 10.1016/s0140-6736(02)09709-x.

Congestive heart failure and expression of myocardial urotensin II.

Lancet. 2002 Jun 8;359(9322):1990-7. doi: 10.1016/S0140-6736(02)08831-1.

Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II.

J Med Chem. 2002 Apr 25;45(9):1799-805. doi: 10.1021/jm0111043.

High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

Cardiovasc Res. 2002 Feb 1;53(2):341-7. doi: 10.1016/s0008-6363(01)00485-0.

Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):141-9. doi: 10.1007/s00210-001-0503-0. Epub 2001 Nov 20.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Cardiovascular actions of human urotensin II--considerations for hypertension.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):271-3. doi: 10.1007/s00210-004-0876-y. Epub 2004 Feb 19.

Urotensin II: a vascular mediator in health and disease.

Curr Vasc Pharmacol. 2005 Apr;3(2):159-68. doi: 10.2174/1570161053586930.

[Urotensin II--a newly discovered modulator of cardiovascular functions in vertebrates].

Cesk Fysiol. 2013;62(1):19-25.

Serum urotensin II levels in patients with non-dipper hypertension.

Clin Exp Hypertens. 2013;35(7):506-11. doi: 10.3109/10641963.2012.758276. Epub 2013 Jan 9.

Therapeutic targets in hypertension: is there a place for antagonists of the most potent vasoconstrictors?

Expert Opin Ther Targets. 2008 Mar;12(3):327-39. doi: 10.1517/14728222.12.3.327.

Role of urotensin II in atherosclerotic cardiovascular diseases.

Cardiovasc Revasc Med. 2008 Jul-Sep;9(3):166-78. doi: 10.1016/j.carrev.2008.02.001.

[Possible involvement of urotensin II in essential hypertension].

Nihon Rinsho. 2004 Sep;62 Suppl 9:727-9.

Human urotensin II as a link between hypertension and coronary artery disease.

Hypertens Res. 2006 Jun;29(6):375-87. doi: 10.1291/hypres.29.375.

Urotensin-II as an angiogenic factor.

Peptides. 2010 Jun;31(6):1219-24. doi: 10.1016/j.peptides.2010.03.022. Epub 2010 Mar 24.

Urotensin II: from osmoregulation in fish to cardiovascular regulation in man.

Br J Anaesth. 2007 May;98(5):557-9. doi: 10.1093/bja/aem088.

引用本文的文献

Desensitisation of native and recombinant human urotensin-II receptors.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Nov;380(5):451-7. doi: 10.1007/s00210-009-0441-9. Epub 2009 Aug 13.

Hemodynamic effects of chronic urotensin II administration in animals with and without aorto-caval fistula.

Peptides. 2007 Aug;28(8):1483-9. doi: 10.1016/j.peptides.2007.04.018. Epub 2007 May 6.

Therapeutic potential of blockade of the urotensin II system in systemic hypertension.

Curr Hypertens Rep. 2007 Mar;9(1):53-8. doi: 10.1007/s11906-007-0010-x.

Enhancement of vascular smooth muscle cell migration by urotensin II.

Naunyn Schmiedebergs Arch Pharmacol. 2006 Aug;373(5):381-6. doi: 10.1007/s00210-006-0086-x. Epub 2006 Aug 1.

Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Naunyn Schmiedebergs Arch Pharmacol. 2006 May;373(2):148-57. doi: 10.1007/s00210-006-0057-2. Epub 2006 Apr 5.

Urotensin II stimulates plasma extravasation in mice via UT receptor activation.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):347-52. doi: 10.1007/s00210-004-0991-9. Epub 2004 Oct 23.

本文引用的文献

Urotensin-II: a novel systemic hypertensive factor in the cat.

Naunyn Schmiedebergs Arch Pharmacol. 2004 Mar;369(3):274-80. doi: 10.1007/s00210-004-0873-1. Epub 2004 Feb 19.

Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta.

Br J Pharmacol. 2003 Dec;140(7):1155-8. doi: 10.1038/sj.bjp.0705555.

Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure.

Am J Physiol Heart Circ Physiol. 2003 Oct;285(4):H1576-81. doi: 10.1152/ajpheart.00217.2003. Epub 2003 Jun 5.

Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney.

Am J Physiol Renal Physiol. 2003 Oct;285(4):F792-8. doi: 10.1152/ajprenal.00342.2002. Epub 2003 Jun 3.

Plasma urotensin in human systolic heart failure.

Circulation. 2002 Dec 3;106(23):2877-80. doi: 10.1161/01.cir.0000044388.19119.02.

Plasma urotensin II in heart failure.

Lancet. 2002 Aug 17;360(9332):545-6. doi: 10.1016/s0140-6736(02)09709-x.

Congestive heart failure and expression of myocardial urotensin II.

Lancet. 2002 Jun 8;359(9322):1990-7. doi: 10.1016/S0140-6736(02)08831-1.

J Med Chem. 2002 Apr 25;45(9):1799-805. doi: 10.1021/jm0111043.

High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man.

Cardiovasc Res. 2002 Feb 1;53(2):341-7. doi: 10.1016/s0008-6363(01)00485-0.

Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents.

Naunyn Schmiedebergs Arch Pharmacol. 2002 Feb;365(2):141-9. doi: 10.1007/s00210-001-0503-0. Epub 2001 Nov 20.